益气养阴方结合眶内电针治疗Graves眼病的临床效果

Abstract
Figure/Table
References (24)
Related Citation (15)

Download: PDF (743 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate clinical efficacy of Yiqi Yangyin Decoction combined with intraorbital-electroacupuncture in the treatment of Graves ophthalmopathy (GO). Methods From May 2016 to October 2018, 70 patients with moderate to severe active GO admitted to Hubei Hospital of Traditional Chinese Medicine were selected for retrospective analysis. According to different clinical treatment methods, they were divided into group A and group B, with 35 cases in each group. In group A, methylprednisolone sodium succinate was given intermittently, 0.5 g every week, after six weeks of continuous administration, the dosage was reduced to 0.25 g every week, and then for six weeks. Group B was treated with Yiqi Yangyin Decoction and intraorbital-electroacupuncture for 12 weeks. Traditional Chinese medicine syndrome score, clinical efficacy, exophthalmos, clinical activity score (CAS) and related immune indexes of two groups were compared. Results The scores of traditional Chinese medicine syndromes in both groups after treatment were lower than those before treatment, and those in group B were lower than those in group A (P < 0.05). The total effective rate of group B after treatment was higher than that of group A (P < 0.05). The exophthalmos and CAS in both groups were lower than those before treatment, and those in group B were lower than those in group A (P < 0.05). The levels of TNF-α, IL-6, IL-17 and IGF-1 in both groups were lower than those before treatment, and those in group B were lower than those in group A (P < 0.05). Conclusion Compared with methylprednisolone intermittent treatment, Yiqi Yangyin Decoction combined with intraorbital–electroacupuncture in the treatment of GO can significantly reduce the clinical symptoms and signs of patients, enhance clinical efficacy, improve the patients′ autoimmune function, and promote rehabilitation.

Key words： Yiqi Yangyin Decoction Intraorbital–electroacupuncture Graves ophthalmopathy Clinical efficacy

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	TENG Jinyan1
	2 LI Yang2
	3 WANG Jieyu1
	2 ZUO Xinhe2
	3 DING Deguang1
	2 PAN Hongling1
	2 YU Peihao1
	2

Cite this article:

TENG Jinyan1,2 LI Yang2,3 WANG Jieyu1, et al. Clinical effect of Yiqi Yangyin Decoction combined with intraorbital–electroacupuncture in the treatment of Graves ophthalmopathy[J]. 中国医药导报, 2019, 16(34): 134-137.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2019/V16/I34/134

[1] Wiersinga WM. Advances in treatment of active，moderate-to-severe Graves′ ophthalmopathy [J]. Lancet Diabetes Endocrinol，2017，5（2）：134-142.
[2] 屠晓芳，张洪梅.甲状腺相关性眼病的评估方法及激素治疗进展[J].中国全科医学，2017，20（18）：2294-2298.
[3] 彭细峰，邓江涛，叶静梅，等.羟基喜树碱对甲状腺相关眼病球后成纤维细胞增殖和凋亡的影响[J].中国医药科学，2017，7（17）：26-29.
[4] 吴腾飞，曾娟花，丛亿蕾，等.瘿瘤合剂联合甲巯咪唑对格雷夫斯病患者甲状腺功能及相关细胞因子的影响[J].上海中医药大学学报，2016，30（1）：19-22.
[5] 赵勇，徐文华，陈继东，等.陈如泉教授治疗甲状腺结节的用药经验[J].中西医结合杂志，2014，9（1）：20-22，36.
[6] 龙健，刘纯.2016年欧洲甲状腺协会/欧洲格雷夫斯眼病专家组格雷夫斯眼病指南解读[J].重庆医科大学学报，2016，41（11）：1180-1182.
[7] 中华医学会内分泌学分会《中国甲状腺疾病诊治指南》编写组.中国甲状腺疾病诊治指南—甲状腺功能亢进症[J].中华内科杂志，2007，46（10）：876-882.
[8] 国家中医药管理局.中药新药临床研究指导原则（试行）[M].北京：中国医药科技出版社，2002：240.
[9] 林爱珍，孙光军，陈如泉.益气养阴方对Graves病合并白细胞减少小鼠骨髓细胞CD45分子表达的影响[J].北京中医药，2014，33（11）：865-867.
[10] Mourits MP，Prummel MF，Wiersinga WM，et al. Clinical activity score as a guide in the management of patients with Graves′ ophthalmopathy [J]. J Clin Endocrinol （Oxf），1997，47（1）：9-14.
[11] Zhu W，Ye L，Shen L，et al. A prospective，randomized trial of intravenous glucocorticoids therapy with different protocols for patients with graves′ ophthalmopathy [J]. J Clin Endocrinol Metab，2014，99（6）：1999-2007.
[12] Marius NS，James AG，Rebecca SB. The evaluation and treatment of Graves ophthalmopathy [J]. Med Clin N Am，2012，96：311-328.
[13] 李章芳，沈洁.甲状腺相关眼病治疗研究进展[J].中国实用内科杂志，2013，33（11）：896-898.
[14] Wakelkamp IM，Gerding MN，Van Der Meer JW，et al. Both Th1-and Th2-derived cytokines in serum are elevated in Graves′ ophthalmopathy [J]. Clin Exp Immunol，2000， 121（3）：453-457.
[15] Elenkov IJ. Glucocorticoids and the Th1/Th2 balance [J]. Ann N Y Acad Sci，2004，1024：138-146.
[16] Zheng L，Ye P，Liu C. The role of the IL-23/IL-17 axis in the pathogenesis of Graves′ disease [J]. Endocr J，2013，60（5）：591-597.
[17] 郑莉，陈紫君，刘纯.Th3、Th17及相关细胞因子在自身免疫性甲状腺疾病发病中的作用[J].中国免疫学杂志，2013，29（1）：43-47.
[18] Sinclair SM，Allen KD，Jing L，et al. Interleukin-17 synergizes with IFN-gamma or TNF-alpha to promote inflammatory mediator release and intercellular adhesion molecule-1 （ICAM-1） expression in human intervertebral disc cells [J]. J Orthop Res，2011，29（1）：1-7.
[19] 李红林，高美华，郑云会，等.细胞因子IFN-γ、IL-6、IL-17和TGF-β1在Graves病发病中的作用[J].中国免疫学杂志，2015，31（2）：253-256.
[20] Rybinski B，Franco-Barraza J，Cukierman E. The wound healing，chronic fibrosis，and cancer progression triad [J]. Physiol Genomics，2014，46（7）：223-244.
[21] 俞丹洋，刘凤权，曹芳，等.胰岛素样生长因子1受体在甲状腺相关性眼病眼眶脂肪细胞增殖和分化中的作用[J].第二军医大学学报，2016，37（12）：1488-1494.
[22] Zhao SX，Tsui S，Cheung A，et al. Orbital fibrosis in a mouse model of Graves′ disease induced by genetic immunization of thyrotropin receptor cDNA [J]. J Endocrinol，2011，210（3）：369.
[23] 冯晓娜，赵岐.放射治疗联合糖皮质激素冲击用于重度活动期甲状腺相关性眼病的疗效观察[J].中国医院用药评价与分析，2018，18（10）：1333-1335.
[24] 何伟，刘英.HA和IGF-1检测对甲状腺相关性眼病活动度的评价[J].标记免疫分析与临床，2014，21（4）：401-404.